Since their emergence, mRNA vaccines have carried a quiet contradiction: the same nanoparticles that protect and deliver genetic instructions are drawn instinctively to the liver, an organ that neither needs nor benefits from the encounter. Researchers in Kawasaki, Japan have now addressed this with geometric precision — coating the liver's sinusoid walls with a temporary, biocompatible agent that redirects nanoparticles toward their intended destinations. The work, published in ACS Nano in August 2026, does not reinvent the vaccine; it clears the path the vaccine was always meant to travel.
Researchers develop coating to prevent mRNA nanoparticles from accumulating in liver
Cases of hepatitis following mRNA vaccination have been reported in humans due to unintended liver protein expression, which this method aims to prevent.